David Wyn Watson

This inventor holds 16 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Astrazeneca Ab, Biota Europe Limited. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Wyn Watson. Retrieved from https://idiyas.com/inventor/david-wyn-watson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 4)

% Patents Active = 93.8

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 12.2

ph-index = 6

Forward Citations = 137(Granted Patents)

Company Filing History:

Years Active: 2015-2024

Loading Chart...

Areas of Expertise:

Dipeptidyl Peptidase Inhibitors

Antibacterial Compounds

Oxazepane Derivatives

Pharmaceutical Formulations

Chemical Synthesis

Drug Development

Biochemical Analysis

Medicinal Chemistry

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054465 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2024-08-06),

2. 11814359 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-11-14),

3. 11773069 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-10-03),

4. 11680049 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-20),

5. 11673872 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),

6. 11673871 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),

7. 11667615 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-06),

8. 11655224 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

9. 11655223 - Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

10. 11655222 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

11. 11655221 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

12. 11117874 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2021-09-14),

13. 10669245 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors (2020-06-02),

14. 10287258 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2019-05-14),

15. 9522894 - [object Object] (2016-12-20),

Title: The Innovative Contributions of David Wyn Watson

Introduction

David Wyn Watson is a notable inventor based in Essex, GB, recognized for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, Watson has made strides in developing compounds that have the potential to treat various clinical conditions.

Latest Patents

Among his latest patents are the compounds known as certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides, which serve as dipeptidyl peptidase 1 inhibitors. These compounds are designed to inhibit dipeptidyl peptidase 1 (DPP1) activity, showcasing their utility in treating and preventing respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The patents also cover pharmaceutical compositions containing these compounds and the processes for preparing them.

Career Highlights

David Wyn Watson has worked with prominent companies in the pharmaceutical industry, including AstraZeneca and Biota Europe Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Watson has collaborated with notable colleagues such as Stephen Connolly and Steven Swallow, further enhancing his contributions to the field.

Conclusion

David Wyn Watson's innovative work in developing pharmaceutical compounds highlights his significant role as an inventor. His contributions continue to impact the treatment of respiratory diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.